The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study / Ferdinando, Fusco; Riccardo, Sicuteri; Andrea, Rossi; Stathis, Kontodimas; Jose Maria Haro, ; Ciro, Imbimbo; Mirone, V.; Italian Edos Study Group, ; Aiello, A.; Amici, A.; Aragona, F.; Aragona, C.; Artibani, W.; Austoni, E.; Avolio, A.; Bellastella, A.; Bonifacio, Vincenzo; Bono, A.; Boscaro, M.; Bozzo, W.; Brausi, M.; Breda, G.; Caggiano, S.; Calabro, A.; Calatola, P.; Canovaro, G.; Caraceni, E.; Carani, C.; Casarico, A.; Castiglioni, M.; Ciambrone, G.; Cicalese, V.; Confortin, L.; Conti, G.; D'Agata, R.; Dal Bianco, M.; De Grande, G.; Di Ceglie, F.; Di Lena, S.; Di Santo, V.; D'Ottavio, G.; Enria, T.; Fantaccione, P.; Fasolis, G.; Foglini, P.; Foresta, C.; Forti, G.; Francavilla, S.; Frea, B.; Gasparella, V.; Gattuccio, F.; Gentile, L.; Gentile, V.; Ghigo, E.; Giannini, F.; Guarasci, M.; Guazzoni, G.; Ippoliti, G. B.; Jacobellis, U.; Jannini, E.; La Rocca, L.; Lanzafame, F.; Laudi, M.; Laurenti, C.; Leidi, G.; Lenzi, A.; Leoni, S.; Lombardi, G.; Lotti, T.; Luciani, L.; Luciano, M.; Ludovico, G.; Lunghi, F.; Mancini, P.; Manganelli, A.; Manservigi, D.; Mantero, F.; Marin, A.; Masala, A.; Menchini Fabris, F.; Miano, L.; Monica, B.; Montevecchi, R.; Montorsi, F.; Morrone, G.; Motta, M.; Muzzonigro, G.; Nicita, G.; Oliva, G.; Pagano, S.; Pagliarulo, A.; Paola, Q.; Paolini, R.; Pareo, R. M.; Pavone, C.; Pecoraro, G.; Pinchera, A.; Pino, P.; Pinzi, N.; Pirozzi Farina, F.; Pittaluga, P.; Pizzocaro, A.; Rago, R.; Rizzo, M.; Romanelli, F.; Rovereto, B.; Ruggeri, M.; Salzano, L.; Sanserverino, R.; Savoca, G.; Scarano, P.; Scardapane, R.; Scarpa, R.; Selvaggi, F. P.; Severini, G.; Soli, M.; Spera, G.; Tengalia, R.; Testa, G.; Tracia, A.; Traficante, A.; Turriziani, M.; Usai, E.; Vaccarella, G.; Valenti, P.; Villanova, A.; Vicentini, C.; Vincenti, L.; Vita, A.; Volpi, R.; Zambelli, S.; Zito, A.. - In: ASIAN JOURNAL OF ANDROLOGY. - ISSN 1008-682X. - 11:5(2009), pp. 629-637. [10.1038/aja.2009.48]
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
BONIFACIO, Vincenzo;A. Lenzi;F. Romanelli;
2009
Abstract
The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
